Cheryl Vargo
DVM, MVetSc, DACVIM
Dr. Vargo is a dermatology resident at the University of Georgia. After graduating from the Western College of Veterinary Medicine (WCVM), Saskatoon, Saskatchewan, Canada, in 1999, she was in general practice for 4 years before completing a rotating internship in Greensboro, North Carolina, followed by a residency and a Master of Veterinary Science degree in small animal internal medicine at WCVM. Dr. Vargo obtained ACVIM Diplomate status in 2008 and worked in private specialty practices and at WCVM before pursuing a dermatology internship in 2019 and a Master of Science degree in comparative biomedical science. Dr. Vargo’s main interests are feline and canine atopic dermatitis, canine necrolytic migratory erythema, and autoimmune skin diseases.
Read Articles Written by Cheryl VargoFrane Banovic
DVM, PhD, DECVD
Dr. Banovic graduated from veterinary school in Zagreb, Croatia, and received his PhD in veterinary microbiology from the University of Zagreb. He finished a 1-year rotational internship at the Veterinary School in Munich, Germany, before completing a 3-year dermatology residency at North Carolina State University; afterward, he enrolled in a postdoctoral fellowship in investigative dermatology with a primary research focus on itch in atopic dermatitis and staphylococcal pyoderma. Dr. Banovic favors interdisciplinary approaches to biologic questions and incorporates basic immunology as well as cell biology and biochemical approaches in his research. He is presently an assistant professor of dermatology at the University of Georgia.
Read Articles Written by Frane BanovicThe nomenclature for feline cutaneous allergic skin disease has been recently updated.1 In the past, the term feline hypersensitivity dermatitis was widely used for cutaneous allergic reactions resulting from flares triggered by flea, food, and environmental allergens. The term feline hypersensitivity dermatitis has been replaced with feline atopic syndrome (FAS), which broadly includes feline allergic skin disease, food allergy, and/or asthma.1 Within the new FAS nomenclature, feline atopic skin syndrome (FASS) refers explicitly to allergic skin disease induced by environmental allergens (e.g., dust mites, pollens, molds). This short review focuses on FASS.
FASS is a common pruritic and inflammatory skin disease of cats.1,2 In a large multicenter study on pruritic cats, FASS represented 20% of the study cats, making it one of the most prevalent skin diseases among cats.2 Manifestations of pruritus in cats are scratching, rubbing, chewing, licking, and/or excessive grooming. Cats with diagnosed FASS typically exhibit 1 or more of the following clinical lesion patterns: miliary dermatitis, self-induced symmetrical alopecia, facial head and neck pruritus with excoriations and erosions, and eosinophilic granuloma complex.2-4
- Miliary dermatitis is characterized by multiple erythematous papules that are covered by small crusts typically centered around the neck and, in some patients, may be more visible in the sparsely haired preauricular space (FIGURE 1A).5
- Self-induced symmetric alopecia results from overgrooming and is commonly seen on the abdomen, limbs, and flanks (FIGURE 1B).4
- Facial head and neck pruritus results from excessive scratching around the head and neck, leading to excoriations and erosions. Alopecia and miliary dermatitis can also be associated with this clinical presentation (FIGURE 1C).4
- Eosinophilic granuloma complex encompasses 3 clinical forms: indolent ulcer, eosinophilic plaque, and granuloma. An indolent ulcer, frequently referred to as a rodent ulcer, appears as an ulcerative lesion of the upper lip; the lesion may be unilateral or bilateral and may become quite large when chronic.4 An eosinophilic plaque is an elevated, erythematous, and often eroded-to-ulcerative lesion most commonly found on the ventral abdomen and medial thighs (FIGURE 1D).4 Eosinophilic granuloma can appear as a linear, firm lesion most often on the caudal aspect of the hind limbs, a diffuse swelling of the chin, and/or a proliferative lesion in the mouth.4
In many studies, most cats with FASS were around 3 years of age or younger and females seemed to be overrepresented.4 Although seasonality often plays a role in FASS, nonseasonal signs develop over time in a large percentage of cats.4
Diagnostics and Differential Diagnoses
There is no specific single finding or test for FASS; rather, the diagnosis is based on history, clinical examination findings, exclusion of other pruritic dermatoses, and fulfillment of published diagnostic criteria for FASS.3,4
Excluding Other Causes of Pruritis
Because ectoparasites such as Notoedres, Demodex (i.e., Demodex gatoi), and Otodectes mites can result in pruritus, diagnostics such as superficial skin scrapings, hair plucks, and examination of otic debris should be performed where appropriate.4 An important differential for FASS is flea allergy dermatitis, which necessitates effective adulticidal flea control for the affected cat, any in-contact animals, and the patient’s environment for a minimum of 9 weeks.4
Complication features in cats with FASS are bacterial pyoderma and Malassezia overgrowth, both of which can contribute to pruritus. Skin cytology is simple to perform, and identification and treatment of secondary infections aid in the management of these patients.4
Diagnostic Criteria
Criteria have been established to help with diagnosing food- and/or environment-induced FAS (previously described as non–flea-induced hypersensitivity dermatitis) after flea hypersensitivity has been excluded (BOX 1).3 When 6 of these 10 criteria are met, the sensitivity is 90% and specificity is 83%.3 Although these criteria help differentiate FASS from other causes of pruritus, there is no current means to discriminate FASS from a food allergy.3,4 A food allergy can mimic any of the 4 clinical lesion patterns observed in FAS, and as such, an elimination diet trial using either a novel limited ingredient or a hydrolyzed diet should be performed for a minimum of 8 weeks.4,6 Suggestive of a food allergy are extracutaneous signs involving the gastrointestinal system (vomiting, diarrhea, flatulence) and/or conjunctivitis and/or an older patient in which 1 or more of the clinical lesion patterns develops.4 During the first 5 to 6 weeks of the elimination diet trial, treatment of any secondary skin/ear infections along with resolution of pruritus is necessary before medications can be discontinued and the patient reassessed solely on the diet. If clinical relapse is not noticed within 2 weeks, rechallenge with the previous diet should be performed. Return of clinical signs within 7 days of rechallenge confirms a food allergy diagnosis for 90% of cats and for almost all cats within 14 days.7 Although FASS and a food allergy can be diagnosed for the same patient, a recent review reported that incidence of both conditions is very low (2.4%).4
- Pruritus at onset
- At least 2 of the following classic clinical reaction patterns:
- miliary dermatitis
- symmetric alopecia
- head and neck erosions/ulcerations
- eosinophilic dermatitis
- At least 2 sites affected
- Miliary dermatitis as a dominant pattern
- Eosinophilic dermatitis, symmetric alopecia, or erosions/ulcerations on the head, face, lips, ears, or neck
- Nonsymmetric alopecia on the rump, tail, or hindlimbs
- Symmetric alopecia on the abdomen
Absence of
- Erosions/ulcerations on the forelimbs
- Lesions on the sternum or axilla
- Nodules or tumors
*The term feline non–flea-induced hypersensitivity dermatitis used in reference 3 has now been replaced with feline atopic syndrome.
Intradermal and IgE Testing
No type of allergy testing, whether intradermal and/or serologic allergen-specific IgE testing, should be used to diagnose FASS. Multiple studies have shown no significant differences in measured serum levels of IgE between allergic cats and healthy controls.8,9 In addition, increasing serum levels of IgE have been shown to correspond with age, residing outdoors, and absence of deworming.8 Interpreting results of intradermal skin testing of cats can be challenging due to weak reactions; intravenous fluorescein dye has been recommended to help visualize responses with use of a Wood’s lamp.4 Because avoidance of environmental allergens such as pollens is often impractical, allergy testing and allergen-specific immunotherapy can play a role in the long-term management of cats with FASS. However, allergy testing should only be used to identify allergens in patients undergoing allergen-specific immunotherapy (AIT) and desensitization rather than to diagnose an “allergic cat.”
Treatment of FASS
FASS frequently requires medical therapy, which can present compliance challenges for the patient and the client. Although a recent extensive review proposes several treatments for managing FASS,10 this article reviews use of glucocorticoids, cyclosporine, oclacitinib, and AIT.
Glucocorticoids
The drugs most commonly used to manage FASS are systemic glucocorticoids due to their broad-range anti-inflammatory effects. Systemic glucocorticoids rapidly and effectively ameliorate pruritus and skin lesions in cats with FASS.10,11 A recent study demonstrated a marked (>50%) reduction in pruritus and lesional skin scores (SCORing Feline Allergic Dermatitis [SCORFAD], pubmed.ncbi.nlm.nih.gov/22823903) in FAS cats given dexamethasone sodium phosphate (4 mg/mL) at 0.2 mg/kg PO for 20 to 31 days without significant adverse effects.12
Other glucocorticoids that have shown efficacy in treating allergic cats include triamcinolone and methylprednisolone; mean oral daily induction doses were 0.18 mg/kg and 1.41 mg/kg, respectively.11 Subcutaneous injections of methylprednisolone acetate may seem to be an attractive treatment option for feline patients with refractory FASS and for which oral administration of tablet-type medications is challenging. However, the lack of prospective controlled studies evaluating the dosages, frequency of administration, and efficacy in cats with FASS,13 as well as possible side effects including iatrogenic hyperadrenocorticism,14 suggests a need for careful evaluation of the pros and cons of this treatment.
Cyclosporine
Cyclosporine is a calcineurin inhibitor that inhibits T-cell activation.15 The recommended dosage for cats with FASS, based on 2 randomized, double-blinded, placebo-controlled studies, is 7 mg/kg PO q24h.16,17 In one study, after 42 days of treatment with cyclosporine at the 7 mg/kg PO q24h dosage, the average decrease in total lesion score was 65.1% for 144 cats with FASS compared with 9.2% for the 73 placebo group cats.17 Although the veterinary formulation of cyclosporine (Atopica; Elanco, elanco.us) has been routinely administered to FASS patients, human formulations have also been successfully used for management of FASS.18
When prescribing human cyclosporine, it is imperative to use only the microemulsified (i.e., modified) product because oral bioavailability of this product in both human and veterinary patients is greater than that of the vegetable oil formulation, which is not modified.19 A new liquid formulation of cyclosporine for dogs (Cyclavance; Virbac, vet-us.virbac.com) could potentially be used in an off-label manner for cats as well. After clinical remission has been achieved with cyclosporine, the success rate for tapering the drug to every other day is up to and greater than 70% for FAS cats and greater than 50% for FAS cats when further lowered to twice weekly.20,21 According to multiple studies, the most common side effect of cyclosporine in cats is gastrointestinal disturbance (vomiting, diarrhea),16-18 which lessens with continued use and frequency.20,21
Oclacitinib
Oclacitinib (Apoquel; Zoetis, zoetisus.com), a Janus kinase inhibitor registered for use in dogs with allergic dermatitis,22 has recently garnered a lot of attention in the treatment of FASS. Although the drug is not labeled for use in cats, it has been evaluated in several studies; however, comparing efficacy among the studies is challenging as the dosages used were not the same.23-25 In a recent study, oclacitinib was found to be as efficacious as methylprednisolone for reducing pruritus and skin lesion scores after 28 days.23 Another study found that oclacitinib at 1 mg/kg PO q12h seems to be safe in cats for at least 28 days without significant laboratory abnormalities requiring medical intervention.26 Because the half-life of oclacitinib is shorter in cats (2.3 hours) than in dogs (4.1 hours),27 the current recommended oclacitinib dosage for cats is 1 mg/kg q24h to q12h with informed owner consent along with diligent monitoring.10 Long-term studies looking at the safety of oclacitinib in cats with FASS are needed.
Allergen-Specific Immunotherapy
Allergen-specific immunotherapy is the only treatment for FASS that has the potential to induce tolerance and enable reduction or complete elimination of other long-term treatments.28 Mechanisms of tolerance demonstrated in humans include induction of regulatory T (Treg) cells leading to increased levels of interleukin-10 and transforming growth factor-β, resulting in decreased T helper 2 (Th2) cytokines.29 Lower levels of Th2 cytokines lead to decreased degranulation and tissue infiltration of mast cells, basophils, and eosinophils.29 AIT also induces production of IgG4, which leads to reduced production of allergen-specific IgE.29 As to whether these mechanisms of inducing tolerance are applicable to cats requires further investigation. AIT has traditionally been administered to cats subcutaneously or sublingually; in a recent study that evaluated sublingual administration to 22 cats with feline atopic dermatitis for 1 year, all 16 cats that completed the study showed marked improvement in skin lesions after only 3 months.28 Furthermore, of 7 cats that required oral methylprednisolone at the beginning of the study, discontinuation of this medication was possible for 3 cats and reduction by more than 50% was possible for the other 4 cats by the end of the study.28
Other Treatments
Other products used to treat pruritus and skin lesions in cats include antihistamines, maropitant citrate, essential fatty acids, and palmitoylethanolamide.10
Take-Home Points
- Feline allergic disease has undergone a recent change in terminology. Feline atopic skin syndrome (FASS) refers explicitly to allergic skin disease induced by environmental allergens.
- The major components of FASS are pruritus and inflammation.
- FASS treatment requires a partnership with the client and tailoring of treatments to the individual patient.
- Further study is needed to elucidate the pathogenesis of FASS and the development of more targeted and beneficial therapies.
References
1. Halliwell R, Pucheu-Haston CM, Olivry T, et al. Feline allergic diseases: introduction and proposed nomenclature. Vet Dermatol. 2021;32:8-e2.
2. Hobi S, Linek M, Marignac G, et al. Clinical characteristics and causes of pruritus in cats: a multicentre study on feline hypersensitivity-associated dermatoses. Vet Dermatol. 2011;22(5):406-413.
3. Favrot C, Steffan J, Seewald W, et al. Establishment of diagnostic criteria for feline nonflea-induced hypersensitivity dermatitis. Vet Dermatol. 2011;23(1):45-e11.
4. Santoro D, Pucheu-Haston CM, Prost C, et al. Clinical signs and diagnosis of feline atopic syndrome: detailed guidelines for a correct diagnosis. Vet Dermatol. 2021;32(1):26-e6.
5. Gross TL, Kwochka KW, Kunkle GA. Correlation of histologic and immunologic findings in cats with miliary dermatitis. JAVMA. 1986;189(10):1322-1325.
6. Olivry T, Mueller RS, Prelaud P. Critically appraised topic on adverse food reactions of companion animals (1): duration of elimination diets. BMC Vet Res. 2015;11:225.
7. Olivry T, Mueller RS. Critically appraised topic on adverse food reactions of companion animals (9): time to flare of cutaneous signs after a dietary challenge in dogs and cats with food allergies. BMC Vet Res. 2020;16(1):158.
8. Belova S, Wilhelm S, Linek M, et al. Factors affecting allergen-specific IgE serum levels in cats. Can J Vet Res. 2012;76(1):45-51.
9. Taglinger K, Helps CR, Day MJ, Foster AP. Measurement of serum immunoglobin E (IgE) specific for house dust mite antigens in normal cats and cats with allergic skin disease. Vet Immunol Immunopath. 2005;105(1-2):85-93.
10. Mueller RS, Nuttall T, Prost C, et al. Treatment of the feline atopic syndrome – a systemic review. Vet Dermatol. 2021;32(1):43-e8.
11. Ganz EC, Griffin GE, Keys DA, Flatgard TA. Evaluation of methylprednisolone and triamcinolone for the induction and maintenance treatment of pruritus in allergic cats: a double-blinded, randomized, prospective study. Vet Dermatol. 2012;23(5):387-e72.
12. McClintock D, Austel M, Gogal RM, Banovic F. Oral dexamethasone sodium phosphate solution significantly reduces pruritus and clinical lesions in feline hypersensitivity dermatitis: an open-label study. Vet Dermatol. 2021;32(5):497-e137.
13. Vargo C, Banovic F. Is injectable methylprednisolone acetate valuable for treatment of feline hypersensitivity dermatitis? Vet Dermatol. 2021;32(4):402-403.
14. Ferasin L. Iatrogenic hyperadrenocorticism in a cat following a short therapeutic course of methylprednisolone acetate. J Feline Med Surg. 2001;3(2):87-93.
15. Noli C, Scarampella F. Prospective open pilot study on the use of ciclosporin for feline allergic skin disease. J Small Anim Pract. 2006;47(8):434-438.
16. King S, Favrot C, Messinger L, et al. A randomized double-blinded placebo-controlled study to evaluate an effective ciclosporin dose for the treatment of feline hypersensitivity dermatitis. Vet Dermatol. 2012;23(5):440-447.
17. Roberts ES, Speranza C, Friberg C, et al. Confirmatory field study for the evaluation of ciclosporin at a target dose of 7.0 mg/kg (3.2 mg/lb) in the control of feline hypersensitivity dermatitis. J Feline Med Surg. 2016;18(11):889-897.
18. Vercelli A, Raviri G, Cornegliani L. The use of oral cyclosporin to treat feline dermatoses: a retrospective analysis of 23 cases. Vet Dermatol. 2006;17(3):201–206.
19. Palmeiro BS. Cyclosporine in veterinary dermatology. Vet Clin North Am Small Anim Pract. 2013;43(1):153-171.
20. Roberts E, Tapp T, Trimmer A, et al. Clinical efficacy and safety following dose tapering of ciclosporin in cats with hypersensitivity dermatitis. J Feline Med Surg. 2016;18(11):898–905.
21. Steffan J, Roberts E, Cannon A, et al. Dose tapering for ciclosporin in cats with nonflea-induced hypersensitivity dermatitis. Vet Dermatol. 2013;24(3):315–322.
22. Cosgrove SB, Wren JA, Cleaver DM, et al. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013;24(6):587–597.
23. Noli C, Matricoti I, Schievano C. A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood-induced hypersensitivity dermatitis. Vet Dermatol. 2019;30(2):110-114.
24. Ortalda C, Noli C, Colombo S, Borio S. Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats. Vet Dermatol. 2015;26(4):235-238.
25. Pandolfi P, Beccati M. Head and neck feline dermatitis: response to oclacitinib treatment [abstract]. Vet Dermatol. 2016; 27(suppl 1):58.
26. Lopes NL, Campos DR, Machado MA, et al. A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats. BMC Vet Res. 2019;15:137.
27. Ferrer L, Carrasco I, Cristofol C, Puigdemont A. A pharmacokinetic study of oclacitinib maleate in six cats. Vet Dermatol. 2020;31(2):134-137.
28. Foj R, Carrasco I, Clemente F, et al. Clinical efficacy of sublingual allergen-specific immunotherapy in 22 cats with atopic dermatitis. Vet Dermatol. 2021;32(1):67-e12.
29. Berings M, Karaaslan C, Altunbulaki C, et al. Advances and highlights in allergen immunotherapy: on the way to sustained clinical and immunologic tolerance. J Allergy Clin Immunol. 2017;140(5):1250-1267.